Breakfast with Professor Advances in ovarian cancer first-line treatment : The role of anti angiogenics
|
|
- Lorin Shepherd
- 5 years ago
- Views:
Transcription
1 Breakfast with Professor Advances in ovarian cancer first-line treatment : The role of anti angiogenics CLAUDIO CALAZAN Oncologia D Or Oncologistas Associados
2 First-line treatment : The role of anti angiogenics Focus of Discussion Current standart of care in ovarian cancer for locally advanced/ metastatic disease Inhibiting angiogenesis in upfront Active options Complete and ongoing trials Future Prospects up front
3 Ovarian Carcinoma Mininum Standart of Care Maximum attempt at surgical cytoreduction Chemotherapy following surgery
4 Does Cytoreduction Matter? Residual Disease PFS med, m P value OS med, m P value Microscopic 33,0 < 0,001 71,9 < 0,001 0,1-1 cm 16,8 42,4 > 1 cm 14,1 35,0 Platinun Compounds Response Rate Optimal Suboptimal Clinical CR 95% 75% Pathologic CR 50% 25% Winter WE III, et al. J Clin Oncol. 2007;25:3621.
5 FDA-Approved Drugs in Ovarian Cancer
6 Phase III trials in advanced ovarian cancer: no improvement over platinum/taxane Trial n Regimens compared Outcome GOG Cis/cyclo vs cis/cyclo + doxorubicin Efficacy similar; toxicity worse with triplet GOG Observation vs IP 32 P as consolidation IP 32 P not effective GOG Standard cis/cyclo vs dose-intense cis/cyclo Efficacy similar; toxicity worse with dose intense cis GOG GOG IV cisplatin/iv cyclo vs IP cisplatin/iv cyclo IP more effective/less toxic 386 Cis/cyclo vs cis/pac Cis/pac provides better OS OV Cis/cyclo vs cis/pac Cis/pac provides better PFS and OS GOG GOG GOG GOG Cis/pac vs carbo (AUC 9) IP cis/iv pac PFS improved/toxicity worse with IP 648 Cis/pac vs cis vs pac Cis and cis/pac have similar efficacy; combination better tolerated 550 Cis/pac x6 vs cis/pac x3 2 surgery cis/pac x3 No benefit of 2 surgery 792 Cis/pac vs carbo/pac Efficacy similar; tolerability better with carbo/pac ICON3 2,074 Carbo/pac vs carbo vs cyclo/doxorubicin/cis All 3 regimens have similar efficacy; single-agent carbo better tolerated OVAR Cis/pac vs carbo/pac Efficacy similar; tolerability better with carbo/pac Carbo = carboplatin; cis = cisplatin; cyclo = cyclophosphamide; IP = intraperitoneal; IV = intravenous; pac = paclitaxel Omura, et al. JCO 1989; Varia, et al. JCO 2003; McGuire, et al. JCO 1995 Alberts et al. NEJM 1996; McGuire, et al. NEJM 1996; Piccart, et al. JNCI 2000 Markman, et al. JCO 2001; Muggia, et al. JCO 2000; Rose, et al. NEJM 2004 Ozols, et al. JCO 2003; International Collaborative Ovarian Neoplasm Group. Lancet 2002; du Bois, et al. JNCI 2003
7 Phase III trials in advanced ovarian cancer: no improvement over platinum/taxane Trial n Regimens compared Outcome GOG Cis + either 24 h or 96 h pac Efficacy similar AGO- GINECO 1,282 Carbo/pac vs carbo/pac/epirubicin No benefit of a third agent MITO Carbo/pac x6 topo x4 or surveillance No PFS benefit with topo maintenance GOG IV cis/iv pac vs IP cis/ip pac IP has better efficacy/worse toxicity and QoL GCIG 887 Carbo/pac vs carbo/pac/epirubicin No benefit of a third agent AGO- GINECO 1,308 Carbo/pac topo x4 or surveillance No benefit of topo maintenance GOG Cis/pac pac x3 vs x12 cycles in patients in CR PFS improved with pac x12 cycles/no OS difference in a selected patient population GOG ,312 Carbo/pac vs carbo/pac/gem (2 regimens) vs carbo/pac/topo vs carbo/pac/pld No benefit of a third agent OV Carbo/pac x8 vs cis/topo x4 carbo/pac x4 Efficacy similar; tolerability better with carbo/pac AGO- OVAR9 1,742 Carbo/pac vs carbo/pac/gem No benefit of a third agent Carbo = carboplatin; cis = cisplatin; CR = complete response; gem = gemcitabine; IP = intraperitoneal; IV = intravenous; pac = paclitaxel; PLD = pegylated liposomal doxorubicin; topo = topotecan Spriggs, et al. JCO 2007; du Bois, et al. JCO 2006; de Placido, et al. JCO 2004 Armstrong et al. NEJM 2006; Kristensen, et al. Int J Gynecol Cancer 2003 Pfisterer, et al. JNCI 2006; Markman, et al. JCO 2003; Bookman, et al. JCO 2009 Hoskins, et al. JNCI 2010 Markman, et al. Gynecol Oncol 2009; du Bois, et al. JCO 2010
8 Ovarian Cancer: Initial Chemotherapy JGOG: Dose-Dense Weekly Paclitaxel Treatment Arm n Median PFS (mos) Carboplatin AUC 6 Paclitaxel 180 mg/m 2 3 x wkly Carboplatin AUC 6 Paclitaxel 80 mg/m 2 /wk x P Value.015 (HR: (95% CI: ) OS at 3 yrs: wkly (72.1%) > 3 wkly (65.1%); HR: 0.75 (95% CI: ; P =.03) Katsumata N, et al. Lancet. 2009;374:
9 Ovarian Cancer: Initial Chemotherapy Standard frontline chemotherapy is paclitaxel 175 mg/m 2 plus carboplatin AUC 6-7, every 21 days for 6 cycles Result of several studies over last decade GOG 111 [1] and OV 10 [2] : paclitaxel/cisplatin vs cyclophosphamide/cisplatin GOG 158 [3] and AGO OVAR-3 [4] : carboplatin instead of cisplatin 1. McGuire WP, et al. N Engl J Med. 1996;334: Piccart MJ, et al. J Natl Cancer Inst. 2000;92: Ozols RF, et al. J Clin Oncol. 2003;21: du Bois AD, et al. J Natl Cancer Inst. 2003;95:
10 Minimal improvement in ovarian cancer mortality rates no new front-line therapy for >15 years Alkylating agents (melphalan or cyclophosphamide) 20 Platinum-based therapy Platinum/taxane therapy Mortality per 100,000 women Year Jemal et al. CA Cancer J Clin 2009
11 Up front treatment in ovarian cancer: The role of anti angiogenics
12 Tumor Angiogenesis and Neovasculature A, Tumors less than 1 mm 3 receive oxygen and nutrients by diffusion from host vasculature. B, Larger tumors require new vessel network. Tumor secretes angiogenic factors that stimulate migration, proliferation, and neovessel formation by endothelial cells in adjacent established vessels. C, Newly vascularized tumor no longer relies solely on diffusion from host vasculature, facilitating progressive growth.
13 VEGF is an early and persistent promoter of tumour angiogenesis 1 4 VEGF VEGF bfgf TGFβ-1 VEGF bfgf TGFβ-1 PLGF VEGF bfgf TGFβ-1 PLGF PD-ECGF VEGF bfgf TGFβ-1 PLGF PD-ECGF Pleiotrophin Continued VEGF expression 3 Tumours continually require VEGF to recruit new vasculature 5 VEGF continues to be expressed throughout tumour progression, even as secondary pathways emerge 2,3,6,7 1. Bergers, Benjamin. Nat Rev Cancer 2003; 2. Kim, et al. Nature 1993; 3. Folkman. In: DeVita, Hellman, Rosenberg, eds. Cancer: Principles & Practice of Oncology. Vol 2. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins;2005; 4. Ferrara, et al. Nat Med Inoue, et al. Cancer Cell 2002; 6. Mesiano, et al. Am J Pathol 1998; 7. Melnyk, et al. J Urol 1999
14 VEGF is highly expressed in ovarian cancer, with multiple effects Switch from benign to malignant growth pattern 1 Formation of the metastases typical of ovarian cancer on the peritoneum 3 Accumulation of ascites, by increasing peritoneal blood vessel permeability Schumacher et al. Cancer Res Ramakrishnan et al. Angiogenesis 2005; 3. Zhang et al. Am J Pathol Trinh, et al. Br J Cancer 2009; 5. Belotti, et al. Cancer Res 2003
15 VEGF levels correlate with ascites volume in preclinical models VEGF enhances permeability of peritoneal vessels causing ascites development 1 5 Ascites VEGF 750 Positive correlation between ascites volume and VEGF concentrations in a mouse model of ovarian cancer 5 Ascites (ml) VEGF (ng/ml) Time (days) 1. Schumacher et al. Cancer Res 2007; 2. Ramakrishnan et al. Angiogenesis Zhang et al. Am J Pathol 2002; 4. Trinh, et al. Br J Cancer 2009; 5. Belotti, et al. Cancer Res 2003
16 Clinical association of VEGF expression with poor survival creates rationale for its inhibition Survival (%) VEGF ( )/(+) VEGF (++) High VEGF levels (n=39) Low VEGF levels (n=31) p<0.01 (n=31) p<0.01 (n=39) Years Yamamoto, et al. BJC 1997
17 Rationale for Targeting VEGF in Treatment of Epithelial Ovarian Cancer Human tumors VEGF over-expressed in epithelial ovarian cancers, associated with Ascites formation Malignant progression Poor prognosis Preclinical models of solid tumors Anti-VEGF therapy: Slowing of tumor progression Resolution of malignant effusions Synergy with cytotoxic agents Han ES, et al. Expert Rev Anticancer Ther. 2007;7(10): Burger RA. J Clin Oncol. 2007;25(20): VEGF = vascular endothelial growth factor
18 Agents Targeting the VEGF Pathway Anti-VEGF Antibodies VEGF Soluble VEGFRs (bevacizumab) (VEGF-TRAP) Anti-VEGFR Antibodies P P P P VEGFR-1 P P VEGFR-2 Endothelial Cell Podar K, et al. Blood. 2005;105(4): P P Small-Molecule Inhibitors VEGF = vascular endothelial growth factor VEGFR = VEGF receptor
19 GOG0170D: Bevacizumab Progression-Free Survival. 1,0 0,8 0,6 0,4 0,2 0,0 Phase II GOG0170-D AVASTIN (n = 62) 6 m = 0.42 GOG0126 Series (n = 220) Platinum-Resistant Disease 6 m = 0.16 ( SE 0.025) Months on Study Burger et al., Proc Ann Meet ASCO 24:A5009
20 Conclusions -A significant unmet clinical need exists in ovarian cancer, with no treatment innovation over the past 15 years and minimal improvement in outcomes 1 -Ovarian cancer is a VEGF-driven disease, creating a strong rationale to use bevacizumab to improve patient outcomes 2 -Phase II trials indicate that bevacizumab has single-agent activity in ovarian cancer Jemal et al. CA Cancer J Clin 2009; 2. Ramakrishnan, et al. Angiogenesis Burger, et al. JCO 2007; 4. Micha, et al. Int J Gynecol Cancer Penson, et al. JCO 2010
21 GOG-0218 Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal or fallopian tube cancer: A Gynecologic Oncology Group (GOG) study
22 GOG-0218: a randomized, double-blind phase III trial Front-line: epithelial OV, PP or FT cancer Stage III optimal (macroscopic) Stage III suboptimal Stage IV N=1,873 R A N D O M I S E 1:1:1 Bev 15mg/kg Carboplatin AUC6 Paclitaxel 175mg/m 2 Placebo q3w Carboplatin AUC6 Paclitaxel 175mg/m 2 Placebo q3w Carboplatin AUC6 Paclitaxel 175mg/m 2 Bevacizumab 15mg/kg q3w Arm I II III 15 months Stratification variables GOG performance status stage/debulking status OV = ovarian; PP = primary peritoneal FT = fallopian tube; Av =Avastin Burger et al. NEJM 2011;365 (26): Massachusetts Medical Society
23 GOG-0218: key eligibility criteria Histologic diagnosis of epithelial OV, PP, or FT cancer Following maximal debulking surgery: stage III optimal (macroscopic residual disease 1 cm) or suboptimal (>1 cm), or stage IV No prior chemotherapy 1 12 weeks after initial surgery GOG PS 0 2 No history of significant vascular events No evidence of intestinal obstruction requiring parenteral support Written informed consent Burger, et al. NEJM 2011
24 Statistical analysis Primary analysis: Comparison of PFS (investigator-assessed) in each bevacizumab arm vs control Disease progression determined according to RECIST or CA-125 only Planned sample size of 1800 based on: 90% power to detect a PFS hazard ratio (HR) 0.77 Secondary analyses: Overall survival (OS), safety, quality of life and correlative laboratory studies Burger, et al. NEJM 2011
25 GOG-0218: disease assessment CP + Pl/B15 (6 cycles) Maintenance Pl/B15 (16 cycles) Post-treatment follow-up Months Imaging* CA-125 Exam Same intervals for all modalities: every 3 months for 2 years, then every 6 months for 3 years, then annually *Conventional CT or MRI Burger, et al. NEJM 2011 (Supplementary information)
26 GOG-0218: baseline characteristics were well balanced between the three arms Characteristic, % Arm I CP + Pl (n=625) Arm II CP + B15 Pl (n=625) Arm III CP + B15 B15 (n=623) Age in years, median (range) 60 (25 86) 60 (24 88) 60 (22 89) GOG PS 0/1/2, % 50/44/7 50/43/6 49/43/8 Stage/debulking status% III (macroscopic, 1 cm) III (>1 cm) IV Histology % Serous Endometrioid Clear cell Mucinous < Tumour grade, % 1/2/3* Not graded 6/16/71 7 *Grade 3 includes all clear-cell tumours Percentages may not total 100% due to rounding or categorisation 5/14/74 7 3/16/74 8 Burger, et al. NEJM 2011
27 PFS significantly improved with bevacizumab plus chemotherapy and continued as a single agent 1.0 I CP + Pl Pl (n=625) II CP + Bev15 Pl (n=625) III CP + Bev15 Av15 (n=623) Median PFS (months) Stratified analysis HR (95% CI) 0.89 ( ) 0.70 ( ) p value one-sided (log rank) * <0.0001* PFS estimate CP + Pl Pl (Arm I) CP + Bev15 Pl (Arm II) CP + Bev15 Bev15 (Arm III) Time (months) PFS analysis determined using RECIST, global deterioration or CA125 progression p value boundary = Burger et al. NEJM 2011;365 (26): Massachusetts Medical Society
28 Significant PFS improvement, censored for CA-125 events and non-protocol therapy CP + Pl Pl (n=625) CP + Bev15 Bev15 (n=623) Median PFS (months) Stratified analysis HR (95% CI) 0.62 ( ) p value one-sided (log rank) <0.0001* PFS estimate CP + Pl Pl 0 CP + Bev15 Av PFS (months) *p value boundary = Data cut-off date: September 29, 2009 Burger et al. NEJM 2011;365 (26): Massachusetts Medical Society
29 GOG-0218: PFS by disease stage and debulking status Arm I CP + Pl Pl Arm II CP + B15 Pl Randomised patients with stage III optimally debulked disease 2,3 Arm III CP + B15 B15 n Median PFS (months) Hazard ratio (95% CI) (0.62, 1.05) 0.66 (0.50, 0.86) Randomised patients with stage III suboptimally debulked disease 3 n ) 242) Median PFS (months) Hazard ratio (95% CI) (0.77, 1.14) 0.78 (0.63, 0.96) Randomised patients with stage IV disease n Median PFS (months) Hazard ratio (95% CI) (0.70, 1.16) 0.64 (0.49, 0.82)
30 GOG-0218: subgroup analyses of PFS Risk factor Total no. of patients Hazard ratio for Bevacizumab (95% CI) Cancer stage and residual lesion size III, macroscopic 1cm Arm II vs Arm I Arm III vs Arm I III, >1cm Arm II vs Arm I Arm III vs Arm I IV Arm II vs Arm I Arm III vs Arm I Histologic type Serous Arm II vs Arm I Arm III vs Arm I Nonserous Arm II vs Arm I Arm III vs Arm I Tumour grade 1 or 2 Arm II vs Arm I Arm III vs Arm I 3 Arm II vs Arm I Arm III vs Arm I ,066 1, bevacizumab better Control better Burger et al. NEJM 2011;365 (26): Massachusetts Medical Society
31 GOG-0218: subgroup analyses of PFS (cont d) Risk factor Total no. of patients Hazard ratio for Bevacizumab (95% CI) GOG performance status score 0 Arm II vs Arm I Arm III vs Arm I or 2 Arm II vs Arm I Arm III vs Arm I Age <60 years Arm II vs Arm I Arm III vs Arm I years Arm II vs Arm I Arm III vs Arm I years Arm II vs Arm I Arm III vs Arm I bevacizumab better Control better Burger et al. NEJM 2011;365 (26): Massachusetts Medical Society
32 GOG-0218: independent review confirms the PFS benefit IRC-assessed PFS analysis CP + Pl Pl (n=625) CP + Bev15 Bev15 (n=623) Investigator-assessed censored PFS analysis CP + Pl Pl (n=625) CP + Bev15 Bev15 (n=623) Median (months) PFS, months Hazard ratio, stratified (95% CI) 0.62 ( ) 0.62 ( )
33 GOG-0218: conclusions GOG-0218 met the primary objective in the front-line treatment of advanced ovarian (epithelial OV, PP and FT) cancer PFS with CP + Bevacizumab Bevacizumab single agent (Arm III) statistically superior to CP (Arm I) alone Survival effect may be masked by discontinuation of drug or subsequent treatment with bevacizumab after trial Treatment regimen was generally well tolerated; adverse events similar to previous bevacizumab studies CP + bevacizumab bevacizumab single agent can be considered as a standard option
34
35 Safety data on Bevacizumab
36 GI Perforations with Bevacizumab in Ovarian Cancer Study Burger (GOG 170D) 0/62 (0) Garcia (ASCO 2005) 2/29 (6.9) Wright (ASCO 2006) 4/62 (6.5) Monk (Gyn Oncol 2006) 1/32 (3.1) Wright (Cancer 2006) 2/23 (8.7) Bidus (Gyn Oncol 2006) 0/3 (0) Penson (ASCO 2006) 0/30 Total 16/298 (5.4%) Han E, et al. Gynecol Oncol. 2007;105(1):3-6. GI = gastrointestinal
37 Bevacizumab - Toxicity Proteinuria (usually G1 G2) Muco-cutaneous hemorrhage Common G1 epistaxis Rare (possibly life-threatening) G2-G4 tumor site hemorrhage (primarily lung cancer trials) Arterial thromboembolism Uncommon (3% - 5%) Risk factors: age > 65, prior arterial TE Risk of venous thromboembolism not increased GI perforation wound healing Perforation uncommon (2% - 4% in solid tumor population) Wound dehiscence rate 1% Han ES, et al. Expert Rev Anticancer Ther. 2007;7(10): Burger RA. J Clin Oncol. 2007;25(20): G1, G2 = immunoglobulins GI = gastrointestinal TE = thromboembolism
38 Summary of safety: GOG-0218 and ICON7 Grade 3 AE, % Pla + chemo (N=601) GOG-0218 a Bev 15 + chemo (N=607) Chemo (N=763) ICON7 Bev chemo (N=746) Hypertension GI perforation/fistula/abscess Proteinuria Wound-healing complication Non-CNS bleeding CNS bleeding ATE VTE Neutropenia b Febrile neutropenia CHF RPLS a Regulatory analysis; b Includes laboratory abnormality for GOG-0218.
39
40
41
42
43 Summary Angiogenesis plays a key role in ovarian tumor growth and development Several compounds are potents inhibitors of proangiogenic factors such as VEFGFR, FGFR, and others and demostrating clinical activity in ovarian cancer Today only one agent (bevacizumab) is confirmed to improve PFS vs standart treatment. Waiting for confirmative studies for others (pazopanib, nintedanib, AMG 386) Then biomarkers and subgroups analyses would be the next step to help us the righ drug for the right patients at the right time
44 Thank you!
Side Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationRandomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationTarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationCómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H
Cómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H Andres Poveda Fundación Instituto Valenciano de Oncología
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationNew Treatments for Early Ovarian Cancer. Jonathan Ledermann UCL Cancer Institute University College London
New Treatments for Early Ovarian Cancer Jonathan Ledermann UCL Cancer Institute University College London Lucerne Oct 213 Progression-free survival in first-line trials of platinum-based chemotherapy 1998
More informationCo-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG
OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery
More informationTRUST Trial on Radical Upfront Surgical Therapy
AGO OP.7 / TRUST TRUST Trial on Radical Upfront Surgical Therapy A close international cooperation ENGOT ov33 Ongoing Trials status update AGO-OVAR OP.7 / TRUST ENGOT-ov33 Trial setting: Sponsor: Pt with
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationTREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationRANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED
RANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED CHEMOTHERAPY FOR HIGH- RISK STAGE I AND STAGE II-IV OVARIAN
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationOriginal Research. Background
Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,
More informationMedia Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011
Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived
More informationLate recurrent epithelial ovarian cancer
Late recurrent epithelial ovarian cancer Dominic Richards University of Cape Town and New Somerset Hospital Gynaecological Oncology Unit September 2016 LATE RECURRENT EPITHELIAL OVARIAN CANCER Background
More informationNOVITA NEL TRATTAMENTO DELLE NEOPLASIE GINECOLOGICHE: OVAIO
SUPERNOVAE IN ONCOLOGIA Pisa 13-14 Novembre 2015 Domenica Lorusso Gynecologic Oncologic Unit National Cancer Institute-Milan NOVITA NEL TRATTAMENTO DELLE NEOPLASIE GINECOLOGICHE: OVAIO % of Patients Surviving
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationBEVACIZUMAB in Ovarian cancer. Cancer drug fund application and approval is required for funding. Continue Bevacizumab treatment for up to 18 cycles.
BEVACIZUMAB in Ovarian cancer Page 1 of 5 Indication: First line treatment in advanced (Stage IIIc/IV) ovarian cancer, either sub-optimally debulked at primary or delayed primary surgery, or not suitable
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationASCO- GYN Abstracts 8/3/2011. Susana Campos, MD, MPH. Boston Mass. Prevention. Maintenance. Recurrent Disease.
ASCO- GYN- 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Boston Mass Prevention Maintenance Recurrent Disease Abstracts 5001: Effect of screening on ovarian cancer mortality in the Prostate,
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationCurrent options and future opportunities in platinum-resistant ovarian cancer. Aknar Calabrich AMO
Current options and future opportunities in platinum-resistant ovarian cancer Aknar Calabrich AMO LACOG CONFERENCE 2013 Current options and future opportunities in platinum-resistant ovarian cancer Aknar
More informationOvarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationJ Clin Oncol 30: by American Society of Clinical Oncology INTRODUCTION
VOLUME 30 NUMBER 17 JUNE 10 2012 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab
More informationBackground. TAP, Paclitaxel + Doxorubicin + Cisplatin
A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA; stage
More informationResidual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany
Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany What Are Our Questions Q1: Prognostic factor residual disease? Q2: Differences
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationBevacizumab in the treatment of epithelial ovarian carcinoma
es Bevacizumab in the treatment of epithelial ovarian carcinoma In recent years, inhibitors of angiogenesis have become a focus of clinical trials aimed at expanding treatment options for women afflicted
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationTrabectedina + PLD nel trattamento del carcinoma ovarico. Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano
Trabectedina + PLD nel trattamento del carcinoma ovarico Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano The old definition of Recurrent Ovarian Cancer P R I M A R Y T H E
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationExpert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair. December 13, 2016
Expert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair December 13, 2016 1 Forward-Looking Statements This presentation includes forward-looking statements based on management's
More informationAvastin NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. bevacizumab (rch)
NAME OF THE MEDICINE Avastin bevacizumab (rch) CAS 216974-75-3 Bevacizumab is an immunoglobulin G (IgG) composed of two identical light chains, consisting of 214 amino acid residues and two 453 residue
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationFDA APPROVES AVASTIN FOR THE MOST COMMON TYPE OF KIDNEY CANCER
NEWS RELEASE Media Contact: Amy Berry (650) 467-6800 Advocacy Contact: Kristin Reed (650) 467-9831 Investor Contacts: Kathee Littrell (650) 225-1034 Karl Mahler 011 41 61 687 85 03 FDA APPROVES AVASTIN
More information10/24/14. Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches. Disclosure. Learning Objectives
10/24/14 Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches Jessica Gahres, PA-C Memorial Sloan Kettering Cancer Center Don S. Dizon, MD Massachusetts General Hospital Cancer
More informationOvarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress?
Esteemed Physician Humanitarian Distinguished Citizen Disclosure Ovarian Cancer The State of Ovarian Care in the US Why aren t we making more progress? Dr. Goff has indicated that she has no relevant financial
More informationBevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced
More informationAHFS Final. IV and intraperitoneal regimen for. Criteria Used in. Strength. Strength. Use: Based on. taxane (either IV. following
AHFS Final Determination of Medical Acceptance: Off-label Use of Sequential IV Paclitaxel, Intraperitoneal Cisplatin, and Intraperitoneal Paclitaxel for Initial Adjuvan nt Treatment of Optimally Debulked
More informationOriginal Research. Open Access
To cite: Milani A, Kristeleit R, McCormack M, et al. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationTechnology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta284
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta284 NICE 2017.
More informationGYNECOLOGICAL CANCERS
SAMO FoROMe Post ESMO 17 th October 2014, Bern GYNECOLOGICAL CANCERS Cristiana Sessa Oncology Institute of Southern Switzerland Bellinzona CONTENT Antiangiogenics in cervical cancer Antiangiogenics and
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationAvastin (bevacizumab)
Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin
More informationA Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and
Randomized study of sequential cisplatintopotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationBevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials
Arch Gynecol Obstet (2013) 288:655 666 DOI 10.1007/s00404-013-2820-1 GYNECOLOGIC ONCOLOGY Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials
More informationMITO Phase III TRIALS. May 2009
MITO Phase III TRIALS Sandro Pignata MD PhD May 2009 Liposomal doxorubicin stealth vs carboplatin/paclitaxel in recurrent ovarian cancer patients with platinumfree interval between 6-12 months MITO 8 ENGOT
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationGastric cancer and lung cancer impose a substantial
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non Small-Cell Lung Cancer By Loretta Fala, Medical Writer Gastric cancer and lung cancer impose a substantial
More informationOVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary)
1 OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary) Source: UpToDate 2015, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationBevacizumab for the treatment of recurrent advanced ovarian cancer
Bevacizumab for the treatment of recurrent advanced ovarian cancer ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/40 Page 2 This document contains errata in respect
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin
More information